Release Date: November 26, 2025
Expiration Date: November 26, 2026
Activity Overview
This online activity is designed to update clinicians on data presented at the 25th EURETINA Congress that was held from September 4 to 7, 2025, in Paris, France; the 59th Annual Meeting of the Retina Society that was held on September 23 to 26, 2025, in Los Angeles, California; and the American Academy of Ophthalmology that was held in on October 18 to 20, 2025, in Orlando, Florida. Expert thought leaders provide insights to help clinicians apply these findings to managing patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and/or retinal vein occlusion (RVO) when using newer therapies that support longer treatment intervals.
Target Audience
This educational activity is designed to provide expert perspectives on data presented in fall of 2025 regarding the treatment of nAMD, DME, and/or RVO.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize emerging evidence regarding the management of nAMD
- Summarize emerging evidence regarding the management of DME
- Identify
appropriate patient populations who may benefit from evidence-based therapies
used in the management of RVO based on clinical presentation and goals of
treatment